This slide was created under the auspices of Professional Postgraduate Services® through an unrestricted educational grant.
- The Japan EPA Lipid Intervention Study (JELIS) evaluated the effects of eicosapentaenoic acid (EPA; n-3 polyunsaturated fatty acid) on coronary artery disease (CAD) among subjects with hypercholesterolemia but no evidence of coronary artery disease (CAD; n=14,981).
- Subjects with abnormal TG and HDL-C levels (TG ≥150 mg/dL; HDL-C <40 mg/dL) had an increased CAD hazard ratio (HR, 1.71; 95% confidence interval [CI], 1.11–2.64; P=0.014) vs subjects with normal levels.
- As shown in the slide, EPA treatment suppressed the risk for CAD among individuals with abnormal TG and HDL-C levels by 53% (HR, 0.47; 95% CI, 0.23–0.98; P=0.043).
- The authors concluded that given the reduction in CAD event incidence among subjects with elevated TG and low HDL-C, EPA may beneficial for subjects with this dyslipidemic pattern.
Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200(1):135-140.